RDD1609 as a Treatment for Idiopathic Pruritus Ani

RDD1609 as a Treatment for Idiopathic Pruritus Ani: A Randomized Double Blinded Placebo Controlled Crossover Study

This is a double-blind, randomized, placebo-controlled, crossover trial, to test the hypothesis that RDD1609 is effective in treating idiopathic pruritus ani.

Study Overview

• Status: Withdrawn
• Conditions: Idiopathic Pruritus Ani
• Intervention / Treatment: Drug: RDD1609; Drug: Mebendazole 100 MG

Detailed Description

This is a phase 2a randomized double-blinded placebo-controlled cross-over design study in patients with idiopathic pruritus ani. 24 patients, male and females, aged 18 -65 with severe idiopathic pruritus ani (VAS score above 60), will be randomized to this study.

Patients that meet all inclusion criteria and do not have exclusion criteria at randomization visit will be randomly assigned to one of the two treatment groups:

Group 1 will receive 3 weeks of RDD1609 for 3 weeks, followed by 3 weeks of treatment with placebo.

Group 2 will receive 3 weeks of treatment with placebo followed by 3 weeks of treatment with RDD1609.

• Study Type: Interventional
• Phase: Phase 2

Contacts and Locations

Study Locations

• United Kingdom
  • Atherstone, United Kingdom, CV9 1EU
    • The Atherstone Surgery
  • Bristol, United Kingdom, IG95LP
    • University Hospitals Bristol NHS Foundation Trust- Location Bristol Royal Infirmary
  • Buckhurst Hill, United Kingdom, IG95LP
    • Kings Medical Centre
  • Watford, United Kingdom, WD25 7NL
    • Sheepcot Medical Centre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. An Institutional Review Board (IRB) approved informed consent is signed and dated prior to any study-related activities.
2. Male and female patients, age 18 - 65 years with idiopathic PA.
3. Screening VAS for itching of 60 mm and above.
4. Female subjects of child-bearing potential must have a negative urine pregnancy test. Females of childbearing potential must practice a highly effective method of pregnancy prevention (defined as <1% pregnancies per 100 women per year) from one month before screening to one month after the follow-up visit, such as: surgical sterilization, hormonal implant, intrauterine device, or male condom + female diaphragm + vaginal spermicide. Female subject with any of the following circumstances is not required to use a highly effective method of pregnancy prevention: status post-hysterectomy; or, status post-tubal ligation; or, post-menopausal state (defined as >= 12 months of spontaneous amenorrhea) or < 12 months of spontaneous amenorrhea with a blood follicle stimulating hormone > 40 MIU/ml.
5. Subject has normal (or abnormal and clinically insignificant) laboratory values at Screening.
6. Subject has the ability to understand the requirements of the study and a willingness to comply with all study procedures.
7. Subject has not used and agrees to abstain from taking any prescription or non-prescription medications, cosmetics, including herbal and dietary supplements (such as St. John's wort) within 7 days prior to the first dose of study medication (unless authorized by the Investigator and Medical Monitor).

Exclusion Criteria:

1. Known hypersensitivity to RDD1609.
2. Known hypersensitivity to Mebendazole.
3. Previously treated with methylene blue for pruritus ani.
4. Randomization VAS for itching that is <25 mm than the screening VAS.
5. Anorectal conditions such as malignant tumors of the anus and rectum, inflammatory bowel disease, fistulain- ano, fissure-in-ano, incontinence, condylomata, and second- and third-degree hemorrhoids and any other anorectal conditions that requires medicinal treatment.
6. Patients who had previous major proctological surgery.
7. Generalized skin disorders.
8. Active psychiatric disorders.
9. Diabetes mellitus all types.
10. Known to be HIV positive.
11. Current or within the last 4 weeks steroid or pregabalin or gabapentin or antihistamine systemic or local treatment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: CROSSOVER
• Masking: TRIPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: RDD1609 followed by Placebo; Application on the perianal area BID	Drug: RDD1609; RDD1609 to be applied on the perianal area BID; Drug: Mebendazole 100 MG; Mebendazole 100 mg single dose (single prophylactic dose of the anthelmintic medicine); Other Names: Vermox
EXPERIMENTAL: Placebo followed by RDD1609; Application on the perianal area BID	Drug: RDD1609; RDD1609 to be applied on the perianal area BID; Drug: Mebendazole 100 MG; Mebendazole 100 mg single dose (single prophylactic dose of the anthelmintic medicine); Other Names: Vermox

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Visual Analogue Scale (VAS) for itching	Change in severity of itch, measured using Visual Analogue Scale score for itching from baseline through the end of treatment. The Visual Analogue Scale is a 10-cm long line (oriented horizontally), on which patients indicate the severity of their itching by crossing the line at the point that corresponded to their itching severity. The left end of the line indicates "no itch" and right end of the line indicates "worth itch ever".	3 weeks
Pruritus Ani Severity Index score	Effect of RDD1609 on the Pruritus Ani Severity Index score (Mild, Moderate, Severe, Chronic), which is a grading system used to describe severity of physical findings in patients with pruritus ani.	3 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and Tolerability of RDD1609 ( the frequency of adverse events and serious adverse events)	Will be based primarily on the frequency of adverse events and serious adverse events. Other safety data will be summarized as appropriate.	3 weeks

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dermatology Life Quality Index	Effect of treatment on Dermatology Life Quality Index.	3 weeks

Collaborators and Investigators

• Sponsor: RDD Pharma Ltd
• Investigators: Study Chair: Nir Barak, MD, RDD Pharma Ltd; Principal Investigator: Jeanette Melrose, MD, The Atherstone Surgery

Study record dates

Study Major Dates

• Study Start (ANTICIPATED): May 1, 2020
• Primary Completion (ANTICIPATED): November 30, 2020
• Study Completion (ANTICIPATED): December 31, 2020

Study Registration Dates

• First Submitted: November 25, 2018
• First Submitted That Met QC Criteria: November 27, 2018
• First Posted (ACTUAL): November 28, 2018

Study Record Updates

• Last Update Posted (ACTUAL): November 3, 2022
• Last Update Submitted That Met QC Criteria: October 31, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Skin Diseases; Gastrointestinal Diseases; Intestinal Diseases; Rectal Diseases; Skin Manifestations; Anus Diseases; Pruritus; Pruritus Ani; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antiparasitic Agents; Antinematodal Agents; Anthelmintics; Mebendazole; Piperazine; Piperazine citrate; DMP 777
• Other Study ID Numbers: RDD123

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No